Novel piperazine‐based ionizable lipid nanoparticles allow the repeated dose of mRNA to fibrotic lungs with improved potency and safety
Authors:
Open Access
- 28 May 2023
- journal article
- research article
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 8 (6) , e10556
Abstract
MRNA‐based protein replacement therapy has received much attention as a novel intervention in clinical disease treatment. Lipid nanoparticles (LNPs) are widely used for their therapeutic potential to efficiently deliver mRNA. However, clinical translation has been hampered by the immunogenicity of LNPs that may aggravate underlying disease states. Here, we report a novel ionizable LNP with enhanced potency and safety. The piperazine‐based biodegradable ionizable lipid (244cis) was developed for LNP formulation and its level of protein expression and immunogenicity in the target tissue was evaluated. It was found that 244cis LNP enabled substantial expression of the target protein (human erythropoietin), while it minimally induced the secretion of monocyte chemoattractant protein 1 (MCP‐1) as compared to other conventional LNPs. Selective lung targeting of 244cis LNP was further investigated in tdTomato transgenic mice with bleomycin‐induced pulmonary fibrosis (PF). The repeated administration of 244cis LNP with Cre recombinase mRNA achieved complete transfection of lung endothelial cells (~80%) and over 40% transfection of Sca‐1‐positive fibroblasts. It was shown that 244cis LNP allows the repeated dose of mRNA without the loss of activity due to its low immunogenicity. Our results demonstrate that 244cis LNP has great potential for the treatment of chronic diseases in the lungs with improved potency and safety.Keywords
Funding Information
- Korea Disease Control and Prevention Agency (2021ER240300)
- Ministry of Food and Drug Safety (22203MFDS405)
- Ministry of Science and ICT, South Korea (2018M3A9H3020844, 2020R1A2C2004364, 2022M3A9H1014125)
- Ministry of Science and ICT, South Korea (2022M3E5F1081328)
This publication has 23 references indexed in Scilit:
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisNew England Journal of Medicine, 2018
- A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human PrimatesMolecular Therapy, 2018
- Rapid, Single-Cell Analysis and Discovery of Vectored mRNA Transfection In Vivo with a loxP-Flanked tdTomato Reporter MouseMolecular Therapy Nucleic Acids, 2018
- Systemic Messenger RNA Therapy as a Treatment for Methylmalonic AcidemiaCell Reports, 2017
- Tools for translation: non-viral materials for therapeutic mRNA deliveryNature Reviews Materials, 2017
- Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosisBMC Pulmonary Medicine, 2016
- Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening DesignsNano Letters, 2015
- mRNA-based therapeutics — developing a new class of drugsNature Reviews Drug Discovery, 2014
- Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**Angewandte Chemie International Edition, 2012
- Pulmonary fibrosis: pathogenesis, etiology and regulationMucosal Immunology, 2009